At a glance: Pipeline Strong innovative pipeline Our current pipeline has a very promisingrange of late stage assets andwe will seek to add to these throughbusiness development.
LDX Japan ADHD SHP606 SHP602 Lifitegrast FerroKin Dry Eye Disease Iron overload LDX SHP613 BED Acute Vascular Repair FIRAZYR ACE inhibitor SHP607 -induced AE SHP611 PREMIPLEX 1 MLD Prevention of ROP INTUNIV EU ADHD CINRYZE IV SHP609 low vol Hunter CNS XAGRID HAE Prophylaxis SHP555 US Chronic Japan SHP610 Discovery 3 4 Constipation Essential 2 CINRYZE SC Sanfilippo A and preclinical Thrombocythaemia HAE Prophylaxis assets focused INTUNIV MARIBAVIR on rare VP20629 CMV in transplant Japan VPRIV Japan diseases Friedreichs Ataxia patients ADHD Gaucher Discovery & Phase Phase Phase Registration & preclinical One Two Three Phase Four NOTES Lisdexamfetamine dimesylate, active ingredient in VYVANSE ELVANSE 1 SHP611 is currently in a Phase 1 2 clinical trial 2 SHP610 has completed its Phase 1 2 clinical trial and preparation is underway for a Phase 2b trial 3 Discussions are planned with the FDA to determine potential clinical development pathways 4 Subcutaneous formulation 16 SHIRE PLC ANNUAL REPORT 2013 WWW.
COM Governance Financial statements Other information Strategic report Multiple pipeline milestones expected 2014 2015 INTUNIV EU SHP607 ROP VYVANSE MARIBAVIR MAA submission Phase 2 headline Head to Head versus Phase 2 headline data Concerta Phase 4 data data SHP613 AVF SHP602 Phase 2 headline Phase 2b iron overload data headline data study 203 WWW.
COM ANNUAL REPORT 2013 SHIRE PLC 17
